The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape

SIMPLE SUMMARY: Clinical trials have demonstrated the effectiveness of pazopanib as a primary treatment for metastatic renal cell carcinoma (mRCC). The approval of tyrosine kinase inhibitors and checkpoint-inhibitors represented further progress in the mRCC treatment landscape. Yet, with the recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Doehn, Christian, Bögemann, Martin, Grünwald, Viktor, Welslau, Manfred, Bedke, Jens, Schostak, Martin, Wolf, Thomas, Ehneß, Rainer, Degenkolbe, Elisa, Witecy, Stefanie, Goebell, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688275/
https://www.ncbi.nlm.nih.gov/pubmed/36428579
http://dx.doi.org/10.3390/cancers14225486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688275/
https://www.ncbi.nlm.nih.gov/pubmed/36428579
http://dx.doi.org/10.3390/cancers14225486

Ejemplares similares